Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:Deoxyamidinoproclavaminic acid)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST004153 AN006895 Multi-omics Study of Small Intestine Adaptation After Total Colectomy in a Rat model Feces Rat Shanghai Jiao Tong University LC-MS
ST003778 AN006205 Human to mouse microbiota transfer model demonstrates disease-modifying effects of the short-chain fatty acid biotherapy modified microbiota Feces Mouse Diabetes University of Queensland LC-MS
ST003521 AN005782 Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii Bacterial cells Acinetobacter baumannii Bacterial infection Monash University LC-MS
ST003521 AN005783 Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii Bacterial cells Acinetobacter baumannii Bacterial infection Monash University LC-MS
ST003144 AN005159 On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity Blood Plasmodium falciparum Malaria Monash University LC-MS
ST003053 AN005007 Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics Bacterial cells Staphylococcus aureus Bacterial infection Monash University LC-MS
ST003036 AN004978 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 Bacterial cells Pseudomonas aeruginosa Bacterial infection Monash Institute of Pharmaceutical Sciences LC-MS
ST003024 AN004958 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 1 Bacterial cells Pseudomonas aeruginosa Monash Institute of Pharmaceutical Sciences LC-MS
ST002792 AN004542 Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002775 AN004517 Zebrafish Retina Regeneration Metabolomics - 3 Days Post Crush Eye tissue Zebrafish Eye disease University of Miami LC-MS
ST002576 AN005612 Role of environmental toxicants in obesity-related cardiovascular disease: Plasma untargeted LC-HRMS analysis (part 1 of 3) Blood Human Heart disease Boston University LC-MS
ST002444 AN003981 Zebrafish Optic Nerve Regeneration Metabolomics - 3 Days Post Crush Eye tissue Zebrafish Eye disease University of Miami LC-MS
ST002306 AN003768 Metabolomics profiling of full extracts of bacterial culture supernatants. Bacterial cells Bacillus megaterium Myalgic encephalomyelitis/chronic fatigue syndrome University of Connecticut LC-MS
ST002306 AN003768 Metabolomics profiling of full extracts of bacterial culture supernatants. Bacterial cells Enterococcus faecium Myalgic encephalomyelitis/chronic fatigue syndrome University of Connecticut LC-MS
ST002108 AN003448 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002094 AN003420 Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) Feces Human Irritable bowel syndrome Mayo Clinic LC-MS
ST002016 AN003284 Metabolomics of COVID patients Blood Human COVID-19 University of Virginia LC-MS
ST000291 AN000465 LC-MS Based Approaches to Investigate Metabolomic Differences in the Urine of Young Women after Drinking Cranberry Juice or Apple Juice Urine Human University of Florida LC-MS
  logo